Logo image of BME

BLACKROCK HEALTH SCIENCES (BME) Stock Overview

USA - NYSE:BME - US09250W1071

37.06 USD
-0.25 (-0.67%)
Last: 9/12/2025, 8:04:00 PM
37.06 USD
0 (0%)
After Hours: 9/12/2025, 8:04:00 PM
Fundamental Rating

2

Taking everything into account, BME scores 2 out of 10 in our fundamental rating. BME was compared to 0 industry peers in the Unkown industry. BME has a bad profitability rating. Also its financial health evaluation is rather negative. BME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BME had positive earnings in the past year.
BME had a positive operating cash flow in the past year.
Of the past 5 years BME 4 years were profitable.
The reported operating cash flow has been mixed in the past 5 years: BME reported negative operating cash flow in multiple years.
BME Yearly Net Income VS EBIT VS OCF VS FCFBME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA 4.36%
ROE 4.4%
ROIC 0.13%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
BME Yearly ROA, ROE, ROICBME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15

1.3 Margins

BME's Profit Margin has declined in the last couple of years.
BME's Operating Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.29%
PM (TTM) 317.04%
GM 100%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
BME Yearly Profit, Operating, Gross MarginsBME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, BME has less shares outstanding
Compared to 5 years ago, BME has more shares outstanding
BME has a worse debt/assets ratio than last year.
BME Yearly Shares OutstandingBME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BME Yearly Total Debt VS Total AssetsBME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 68.65 indicates that BME is not in any danger for bankruptcy at the moment.
BME has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
BME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Even though the debt/equity ratio score it not favorable for BME, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 68.65
ROIC/WACCN/A
WACCN/A
BME Yearly LT Debt VS Equity VS FCFBME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.29 indicates that BME may have some problems paying its short term obligations.
BME has a Quick Ratio of 0.29. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
BME Yearly Current Assets VS Current LiabilitesBME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.59% over the past year.
BME shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.80% yearly.
BME shows a decrease in Revenue. In the last year, the revenue decreased by -7.64%.
The Revenue has been growing by 8.91% on average over the past years. This is quite good.
EPS 1Y (TTM)12.59%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-372.58%
Revenue 1Y (TTM)-7.64%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-10.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BME Yearly Revenue VS EstimatesBME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 23.02, BME is valued on the expensive side.
BME is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 23.02
Fwd PE N/A
BME Price Earnings VS Forward Price EarningsBME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 7.25
EV/EBITDA N/A
BME Per share dataBME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

5

5. Dividend

5.1 Amount

BME has a Yearly Dividend Yield of 8.09%, which is a nice return.
BME's Dividend Yield is rather good when compared to the S&P500 average which is at 2.45.
Industry RankSector Rank
Dividend Yield 8.09%

5.2 History

The dividend of BME has a limited annual growth rate of 3.39%.
BME has been paying a dividend for at least 10 years, so it has a reliable track record.
BME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.39%
Div Incr Years1
Div Non Decr Years10
BME Yearly Dividends per shareBME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

150.00% of the earnings are spent on dividend by BME. This is not a sustainable payout ratio.
BME's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP150%
EPS Next 2YN/A
EPS Next 3YN/A
BME Yearly Income VS Free CF VS DividendBME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M
BME Dividend Payout.BME Dividend Payout, showing the Payout Ratio.BME Dividend Payout.PayoutRetained Earnings

More info and screens

BLACKROCK HEALTH SCIENCES

NYSE:BME (9/12/2025, 8:04:00 PM)

After market: 37.06 0 (0%)

37.06

-0.25 (-0.67%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)09-03 2025-09-03
Earnings (Next)03-05 2026-03-05
Inst Owners21.31%
Inst Owner Change8.71%
Ins Owners0%
Ins Owner Change0%
Market Cap478.82M
Analysts0
Price TargetN/A
Short Float %0.1%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield 8.09%
Yearly Dividend2.67
Dividend Growth(5Y)3.39%
DP150%
Div Incr Years1
Div Non Decr Years10
Ex-Date08-15 2025-08-15 (0.2621)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 23.02
Fwd PE N/A
P/S 63.25
P/FCF 7.25
P/OCF 7.25
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)1.61
EY4.34%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)5.11
FCFY13.78%
OCF(TTM)5.11
OCFY13.78%
SpS0.59
BVpS42.24
TBVpS42.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.36%
ROE 4.4%
ROCE 0.17%
ROIC 0.13%
ROICexc 0.13%
ROICexgc 0.13%
OM 12.29%
PM (TTM) 317.04%
GM 100%
FCFM 871.86%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
ROICexc(3y)0.2%
ROICexc(5y)0.12%
ROICexgc(3y)0.2%
ROICexgc(5y)0.12%
ROCE(3y)0.25%
ROCE(5y)0.16%
ROICexcg growth 3Y199.74%
ROICexcg growth 5Y4.01%
ROICexc growth 3Y199.74%
ROICexc growth 5Y4.01%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 275%
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z 68.65
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.59%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-372.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.64%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-10.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.5%
EBIT growth 3Y185.41%
EBIT growth 5Y8.1%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y106.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.25%
OCF growth 3YN/A
OCF growth 5YN/A